research use only

Pregnenolone Estrogen/progestogen Receptor modulator

Name: Pregnenolone
SKU: S1914
Availability: InStock
Rating: 5 (4 reviews)

Cat.No.S1914

Pregnenolone(3β-Hydroxy-5-pregnen-20-one) is an endogenous steroid hormone, used in the treatment of fatigue, Alzheimer’s disease, trauma and injuries.

Chemical Structure

Molecular Weight: 316.48

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability Specificity

Quality Control

Batch: Purity: 99.85%

99.85

Related Targets	Adrenergic Receptor GPR Androgen Receptor Glucocorticoid Receptor ACE RAAS Opioid Receptor THR PGES Aromatase 5-alpha Reductase CCK receptor Mineralocorticoid Receptor GHSR SSTR TSH Receptor GNRH Receptor PGDS
Related Products	Cholesterol Endoxifen HCl G15 Licochalcone A AZD9496 PHTPP Liquiritigenin Brilanestrant (GDC-0810) Estriol Lasofoxifene Tartrate Equol Genistin (Genistoside) Erteberel (LY500307) Elacestrant (RAD1901) Dihydrochloride GSK5182 Estrogen receptor modulator 1 Estrogen Receptor α Antibody [B10L16] Gypenoside XVII Imlunestrant Dihydroresveratrol (±)-Equol 27-Hydroxycholesterol Menotropin Enclomiphene Citrate Hexestrol Phospho-Estrogen Receptor α (Ser118) Antibody [L4E1] H3B-5942 Zearalenone SLU-PP-332 Gestodene

Chemical Information, Storage & Stability

Molecular Weight	316.48	Formula	C₂₁H₃₂O₂	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	145-13-1	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	3β-Hydroxy-5-pregnen-20-one			Smiles	CC(=O)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)O)C)C

Solubility

In vitro
Batch:

DMSO : 22 mg/mL (69.51 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 22 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC₅₀/Ki	progestogen Receptor ^[1]
In vitro	Pregnenolone induces a large, dose-related increase of both the rate and extent of MAP2-induced tubulin assembly, whereas progesterone, inactive per se, counteracted the stimulatory effect of this compound. This compound-increased assembly of microtubules produces a completely normal structure. ^[1] It preserves microtubule abundance and promotes cell movement during epiboly. ^[2] This chemical results in dramatic reduction in GR nuclear localization in mouse hippocampal cell line (HT-22). It has neuroprotective effects against both glutamate and amyloid beta protein neuropathology. ^[3]
In vivo	Pregnenolone sustains its proliferative activity in vivo and stimulates the growth of LNCaP-tumor xenografts in intact male SCID mice as well as in castrated animals. This compound is shown to activate transcription through the LNCaP androgen receptor (AR), but not the wild-type AR. ^[4] It results in a significant decrease in the accumulation of astrocytes in the proximity of the wound and in a decreased bromodeoxyuridine incorporation in reactive astrocytes of rats. ^[5] Administration of this chemical results in elevations in downstream neurosteroids such as allopregnanolone, a molecule with neuroprotective effects that also increases neurogenesis, decreases apoptosis and inflammation, modulates the hypothalamic-pituitary-adrenal axis, and markedly increases GABA(A) receptor responses. It elevates pregnenolone sulfate, a neurosteroid that positively modulates NMDA receptors. ^[6]
References	[1] https://pubmed.ncbi.nlm.nih.gov/10737804/ [2] https://pubmed.ncbi.nlm.nih.gov/16437115/ [3] https://pubmed.ncbi.nlm.nih.gov/11358277/ [4] https://pubmed.ncbi.nlm.nih.gov/11179903/ [5] https://pubmed.ncbi.nlm.nih.gov/10221674/ [6] https://pubmed.ncbi.nlm.nih.gov/21756978/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT05781009	Recruiting	Alcohol Use Disorder	Yale University\|National Institute on Alcohol Abuse and Alcoholism (NIAAA)	January 8 2024	Phase 2
NCT05903716	Recruiting	Acne Vulgaris	Marmara University	September 15 2022	--
NCT04791124	Unknown status	Down Syndrome	Parc de Salut Mar\|Aelis Farma\|Starlab	January 11 2021	--
NCT03801629	Completed	Drug Effect	Yale University	September 12 2019	Phase 1
NCT03953612	Completed	Cocaine-Related Disorders	Yale University\|National Institute on Drug Abuse (NIDA)	March 12 2019	Early Phase 1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):